‘What’s Really Important Is, What Are We Doing Next?’: Sandoz On Biosimilar Ambitions
Adalimumab, Denosumab, Natalizumab, And Aflibercept All Under Discussion
Executive Summary
In the second part of Generics Bulletin’s exclusive interview with Sandoz’s global head for biosimilars, Peter Stenico, he discusses the company’s various near-term pipeline opportunities, as well as his expectations for LOE opportunities in the next decade.
You may also be interested in...
Polpharma Biologics CEO Discusses Natalizumab Milestone
In the wake of a positive opinion from the EMA’s CHMP recommending granting a marketing authorization for the firm’s Sandoz-partnered natalizumab biosimilar, Polpharma Biologics CEO Michael Soldan talks to Generics Bulletin about the significance of the development.
Triple Threat: EMA Endorses Three First-Time Biosimilars
At an eventful European Medicines Agency committee meeting in July, three biosimilars from Biocon, Sandoz and Fresenius Kabi have become the first for each respective molecule – aflibercept, natalizumab and tocilizumab – to gain the endorsement of the CHMP.
Generics Bulletin Editor’s Picks For Q2 2023
Looking back over the second quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include strategic updates from some of the off-patent industry’s biggest players, several exclusive interviews, and the build-up to the second wave of biosimilar competition to Humira in the US.